ArticleOncotarget2017
Loss of FOXN3 in colon cancer activates beta-catenin/TCF signaling and promotes the growth and migration of cancer cells.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- The clinical and prognostic significance of FOXN3 downregulation in acute myeloid leukaemia.International journal of laboratory hematology · 2020Trial
- Cigarette smoking combines with genetic variants to regulate FOXN3 and associate with bladder cancer risk.Archives of toxicology · 2026Article
- Clinical significance of FOXN3 expression in Indian breast cancer patients.Scientific reports · 2025Article
- Intercellular extrachromosomal DNA copy-number heterogeneity drives neuroblastoma cell state diversity.Cell reports · 2024Article
- MicroRNAs as the Critical Regulators of Forkhead Box Protein Family in Pancreatic, Thyroid, and Liver Cancers.Biochemical genetics · 2023Review
- FOXN3 inhibits the progression of ovarian cancer through negatively regulating the expression of RPS15A.Human cell · 2023Article
- The Regulatory Mechanism of miR-574-5p Expression in Cancer.Biomolecules · 2022Review
- MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer.Biomarker research · 2022Review
- Bioinformatic analysis of FOXN3 expression and prognostic value in pancreatic cancer.Frontiers in oncology · 2022Article
- MAGI2-AS3 restrains proliferation, glycolysis, and triggers apoptosis in acute lymphoblastic leukemia via regulating miR-452-5p/FOXN3 pathway.Iranian journal of basic medical sciences · 2022Article
- Review
- MicroRNA-182 promotes epithelial-mesenchymal transition by targeting FOXN3 in gallbladder cancer.Oncology letters · 2021Article
- Comprehensive RNA Sequencing in Adenoma-Cancer Transition Identified Predictive Biomarkers and Therapeutic Targets of Human CRC.Molecular therapy. Nucleic acids · 2020Article
- Epigenetic Alterations Associated with the Overall Survival and Recurrence Free Survival among Oral Squamous Cell Carcinoma Patients.Journal of clinical medicine · 2020Article
- Nuclear TARBP2 Drives Oncogenic Dysregulation of RNA Splicing and Decay.Molecular cell · 2019Article
- Novel tumor-suppressor FOXN3 is downregulated in adult acute myeloid leukemia.Oncology letters · 2019Article
- The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis.Molecular cancer · 2019Review
- Recent Advances in Understanding FOXN3 in Breast Cancer, and Other Malignancies.Frontiers in oncology · 2019Review
- FGFR1/FOXM1 pathway: a key regulator of glioblastoma stem cells radioresistance and a prognosis biomarker.Oncotarget · 2018Article
- Checkpoint suppressor 1 suppresses transcriptional activity of ERα and breast cancer cell proliferation via deacetylase SIRT1.Cell death & disease · 2018Article
Corrections and comments
- Retraction · 2026-04-17Concerns/Issues about Data · Duplication of/in Image · Error in Materials · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Plagiarism of Image · Results Not Reproducible · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant activation of beta-catenin/TCF is a hallmark of colon cancer. How the functions of nuclear localized beta-catenin are regulated is not fully understood. Here, it was found that FOXN3 (Forkhead box N3) was down-regulated in colon cancer tissues. Forced expression of FOXN3 inhibited the growth, migration and invasion of colon cancer cells, while knocking down the expression of FOXN3 promoted the growth, migration, invasion and metastasis of colon cancer cells. FOXN3 bind to beta-catenin and inhibited beta-catenin/TCF signaling by blocking the interaction between beta-catenin and TCF4. Taken together, these data demonstrated the suppressive roles of FOXN3 in the progression of colon cancer, and indicated that restoring the functions of FOXN3 would be a novel therapeutic strategy for colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.